Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children  

作　　者：Jia Zhu Zijun Zhen Juan Wang Feifei Sun Suying Lu Junting Huang Yizhuo Zhang Xiaofei Sun 

机构地区：[1]Collaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Guangzhou,Guangdong,China [2]Department of Pediatric Oncology,Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China

出　　处：《Pediatric Investigation》2021年第2期112-117,共6页儿科学研究（英文）

基　　金：The authors would like to thank the participants and study staff of Sun Yat-sen Univesity Cancer Center for their contributions to this article.

摘　　要：Importance Burkitt lymphoma with bone marrow involvement and Burkitt leukemia behave aggressively.Thus far,there are limited data concerning survival and toxicity in Chinese children with Burkitt lymphoma or Burkitt leukemia who have undergone treatment with the non-Hodgkin’s lymphoma Berlin-Frankfurt-Münster-90/95(NHL-BFM-90/95)protocol.Objective To analyze outcomes and toxicity in pediatric patients who exhibit Burkitt lymphoma with bone marrow involvement or Burkitt leukemia following treatment with the NHL-BFM-90/95 protocol.Methods Patients aged<18 years with bone marrow involvement/leukemia who were treated with the NHL-BFM-90/95 protocol,with or without rituximab,in Sun Yat-Sen University Cancer Center from April 2004 to December 2018 were included in this retrospective analysis.Results Twenty-five patients were eligible.Burkitt lymphoma with bone marrow involvement and Burkitt leukemia were present in 10 and 15 patients,respectively.Central nervous system infiltration was not observed in any patients.All patients underwent chemotherapy involving NHL-BFM-90/95 protocol.Six courses of treatment were administered to each patient(v-AA-BB-CC-AA-BB-CC).The BFM-90/95 plus rituximab protocol was administered to 13 patients.The median follow-up interval was 31.9 months(range,2.5–158 months).Of the 25 patients,four died:three died of tumor progression and one died of therapy abandonment after relief of tumor lysis syndrome.The estimated 5-year event-free survival and overall survival rates were both 85.8%±5.0%.Interpretation Chinese pediatric patients who exhibit Burkitt lymphoma with bone marrow involvement or Burkitt leukemia can achieve optimal treatment outcomes and exhibit good tolerance when using the NHL-BFM-90/95 protocol.

关 键 词：Burkitt lymphoma Bone marrow Burkitt Leukemia B-CELL PROGNOSIS 

分 类 号：R733[医药卫生—肿瘤]